Posters

Study to evaluate the effectiveness of high frequency deep sclerotomy (HFDS) in treatment of primary open-angle glaucoma (POAG)

Poster Details

First Author: Z.Khatib INDIA

Co Author(s):    V. Shetty   S. Haldipurkar   P. Sankhe              

Abstract Details

Purpose:

To compare the intraocular pressure (IOP), retinal nerve fibre layer (RNFL) thickness, visual field changes and dependency on antiglaucoma medications pre and post HFDS surgery in patients with POAG.

Setting:

Laxmi Eye Institute, Navi Mumbai.

Methods:

92 eyes of 71 patients of POAG who underwent HFDS were included. Patients were evaluated preoperatively, at 3 months postoperative and 6 months postoperative. The following parameters were assessed at the above 3 visits: IOP, superior and inferior RNFL thickness as measured on Optovue OCT, mean deviation (MD) and visual field index (VFI) as recorded by Humphrey 24-2 preimetry, and number of antiglaucoma drugs needed to maintain target IOP.

Results:

Mean± SD IOP at pre, post 3 and 6 months was 20.17±4.99, 17.00±7.19 and 16.14±4.89 mmHg respectively. Mean± SD MD at pre, post 3 and 6 months was -8.05± 9.30, -10.94±8.75 and -11.31±9.54 dB respectively. The mean± SD VFI at pre, post 3 and 6 months was 77.11±26.87, 73.25±29.45 and 71.55±31.88 respectively.The median (IQR) number of medication at pre, post 3 and 6 months were 1(0. 5, 2), 0(0,1) and 0(0,0) respectively. Mean superior/inferior RNFL thickness at pre, post 3 and 6 months was 85.54 / 81.35, 79.22 / 76.64 and 74.17 / 71.06 respectively.

Conclusions:

There was no statistically significant difference in the RNFL thickness on OCT, and in MD and VFI on perimetry among the 3 visits. However, there was a statistically significant reduction in IOP between the prop and 3 month post op visit, and no significant difference in IOP between the 3 and 6 month post op visits. There was significant reduction in number of drugs required post surgery at 3 months, however no change was noted between 3 and 6 months. Thus, HFDS proved to be an effective surgery for reducing IOP and drug dependency in POAG patients.

Financial Disclosure:

None